Diamyd Medical AB (publ) (DMYD-B) - Net Assets
Based on the latest financial reports, Diamyd Medical AB (publ) (DMYD-B) has net assets worth Skr231.63 Million SEK (≈ $24.93 Million USD) as of November 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (Skr302.46 Million ≈ $32.55 Million USD) and total liabilities (Skr70.82 Million ≈ $7.62 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check DMYD-B asset resilience ratio to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | Skr231.63 Million |
| % of Total Assets | 76.58% |
| Annual Growth Rate | -0.78% |
| 5-Year Change | 47.94% |
| 10-Year Change | 856.84% |
| Growth Volatility | 74.19 |
Diamyd Medical AB (publ) - Net Assets Trend (2010–2025)
This chart illustrates how Diamyd Medical AB (publ)'s net assets have evolved over time, based on quarterly financial data. Also explore Diamyd Medical AB (publ) asset portfolio for the complete picture of this company's asset base.
Annual Net Assets for Diamyd Medical AB (publ) (2010–2025)
The table below shows the annual net assets of Diamyd Medical AB (publ) from 2010 to 2025. For live valuation and market cap data, see Diamyd Medical AB (publ) market cap and net worth.
| Year | Net Assets | Change |
|---|---|---|
| 2025-08-31 | Skr280.00 Million ≈ $30.13 Million |
+91.89% |
| 2024-08-31 | Skr145.92 Million ≈ $15.70 Million |
-13.86% |
| 2023-08-31 | Skr169.40 Million ≈ $18.23 Million |
-20.98% |
| 2022-08-31 | Skr214.38 Million ≈ $23.07 Million |
+13.27% |
| 2021-08-31 | Skr189.26 Million ≈ $20.37 Million |
+161.09% |
| 2020-08-31 | Skr72.49 Million ≈ $7.80 Million |
+15.47% |
| 2019-08-31 | Skr62.78 Million ≈ $6.76 Million |
+45.96% |
| 2018-08-31 | Skr43.01 Million ≈ $4.63 Million |
-50.37% |
| 2017-08-31 | Skr86.67 Million ≈ $9.33 Million |
+196.16% |
| 2016-08-31 | Skr29.26 Million ≈ $3.15 Million |
-25.96% |
| 2015-08-31 | Skr39.52 Million ≈ $4.25 Million |
-10.51% |
| 2014-08-31 | Skr44.16 Million ≈ $4.75 Million |
-26.75% |
| 2013-08-31 | Skr60.29 Million ≈ $6.49 Million |
-85.28% |
| 2012-08-31 | Skr409.58 Million ≈ $44.08 Million |
-11.15% |
| 2011-08-31 | Skr460.97 Million ≈ $49.61 Million |
+46.44% |
| 2010-08-31 | Skr314.78 Million ≈ $33.88 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Diamyd Medical AB (publ)'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 23108300000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (August 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | Skr13.95 Million | 4.98% |
| Other Components | Skr884.47 Million | 315.88% |
| Total Equity | Skr280.00 Million | 100.00% |
Diamyd Medical AB (publ) Competitors by Market Cap
The table below lists competitors of Diamyd Medical AB (publ) ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
G3 Global Bhd
KLSE:7184
|
$15.63 Million |
|
Opus One Resources Inc
V:OOR
|
$15.65 Million |
|
Australian Agricultural Projects Ltd
AU:AAP
|
$15.65 Million |
|
Floyd Public Company Limited
BK:FLOYD
|
$15.65 Million |
|
Reading International B Inc
NASDAQ:RDIB
|
$15.63 Million |
|
Saudee Group Bhd
KLSE:5157
|
$15.62 Million |
|
CHARWOOD ENERGY EO -01
F:L5Q
|
$15.60 Million |
|
LogProstyle Inc.
NYSE MKT:LGPS
|
$15.60 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Diamyd Medical AB (publ)'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 145,920,000 to 279,999,000, a change of 134,079,000 (91.9%).
- Net loss of 169,777,000 reduced equity.
- Share repurchases of 315,392,000 reduced equity.
- Other comprehensive income decreased equity by 200,000.
- Other factors increased equity by 619,448,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | Skr-169.78 Million | -60.63% |
| Share Repurchases | Skr315.39 Million | -112.64% |
| Other Comprehensive Income | Skr-200.00K | -0.07% |
| Other Changes | Skr619.45 Million | +221.23% |
| Total Change | Skr- | 91.89% |
Book Value vs Market Value Analysis
This analysis compares Diamyd Medical AB (publ)'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.44x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has increased from 0.13x to 0.44x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2010-08-31 | Skr8.16 | Skr1.08 | x |
| 2011-08-31 | Skr11.19 | Skr1.08 | x |
| 2012-08-31 | Skr28.46 | Skr1.08 | x |
| 2013-08-31 | Skr3.71 | Skr1.08 | x |
| 2014-08-31 | Skr1.73 | Skr1.08 | x |
| 2015-08-31 | Skr1.49 | Skr1.08 | x |
| 2016-08-31 | Skr1.01 | Skr1.08 | x |
| 2017-08-31 | Skr2.43 | Skr1.08 | x |
| 2018-08-31 | Skr0.75 | Skr1.08 | x |
| 2019-08-31 | Skr0.94 | Skr1.08 | x |
| 2020-08-31 | Skr1.02 | Skr1.08 | x |
| 2021-08-31 | Skr2.71 | Skr1.08 | x |
| 2022-08-31 | Skr2.73 | Skr1.08 | x |
| 2023-08-31 | Skr2.16 | Skr1.08 | x |
| 2024-08-31 | Skr1.53 | Skr1.08 | x |
| 2025-08-31 | Skr2.49 | Skr1.08 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Diamyd Medical AB (publ) utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -60.63%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -130597.69%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.26x
- Recent ROE (-60.63%) is below the historical average (-39.32%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2010 | -0.11% | -0.29% | 0.20x | 1.81x | Skr-31.81 Million |
| 2011 | 22.25% | 36.53% | 0.54x | 1.13x | Skr56.47 Million |
| 2012 | -3.97% | -3159.92% | 0.00x | 1.03x | Skr-57.20 Million |
| 2013 | -20.95% | -12633.00% | 0.00x | 1.12x | Skr-18.66 Million |
| 2014 | -36.30% | -3619.41% | 0.01x | 1.16x | Skr-20.45 Million |
| 2015 | -54.14% | -4170.96% | 0.01x | 1.18x | Skr-25.35 Million |
| 2016 | -109.38% | -4228.27% | 0.02x | 1.29x | Skr-34.93 Million |
| 2017 | -29.49% | -2771.69% | 0.01x | 1.14x | Skr-34.22 Million |
| 2018 | -102.19% | -6054.13% | 0.01x | 1.28x | Skr-48.25 Million |
| 2019 | -58.51% | -2342.54% | 0.02x | 1.18x | Skr-43.01 Million |
| 2020 | 13.39% | 2847.21% | 0.00x | 1.24x | Skr2.46 Million |
| 2021 | 31.73% | 23733.60% | 0.00x | 1.06x | Skr41.12 Million |
| 2022 | -48.29% | -22801.10% | 0.00x | 1.10x | Skr-124.95 Million |
| 2023 | -68.52% | -21258.79% | 0.00x | 1.21x | Skr-133.01 Million |
| 2024 | -104.06% | -116807.69% | 0.00x | 1.49x | Skr-166.44 Million |
| 2025 | -60.63% | -130597.69% | 0.00x | 1.26x | Skr-197.78 Million |
Industry Comparison
This section compares Diamyd Medical AB (publ)'s net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $165,054,194
- Average return on equity (ROE) among peers: -81.86%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Diamyd Medical AB (publ) (DMYD-B) | Skr231.63 Million | -0.11% | 0.31x | $15.63 Million |
| 2cureX AB (2CUREX) | $74.34 Million | -25.47% | 0.06x | $4.90 Million |
| Ascelia Pharma AB (publ) (ACE) | $74.33 Million | -147.03% | 0.17x | $40.96 Million |
| AcouSort AB (ACOU) | $15.58 Million | -57.51% | 0.12x | $8.97 Million |
| Active Biotech AB (ACTI) | $188.64 Million | -118.73% | 1.64x | $17.19 Million |
| Alzinova AB (ALZ) | $20.63 Million | -16.51% | 0.08x | $4.97 Million |
| AlzeCure Pharma (ALZCUR) | $182.01 Million | -28.02% | 0.03x | $18.18 Million |
| Annexin Pharmaceuticals AB (ANNX) | $18.81 Million | -234.16% | 0.42x | $11.24 Million |
| Alligator Bioscience AB (ATORX) | $68.52 Million | -112.06% | 0.43x | $14.33 Million |
| BioInvent International AB (BINV) | $219.00 Million | -63.86% | 0.22x | $155.44 Million |
| BioArctic AB (publ) (BIOA-B) | $788.68 Million | -15.19% | 0.14x | $2.59 Billion |
About Diamyd Medical AB (publ)
Diamyd Medical AB (publ) develops precision medicine therapies for the treatment of autoimmune diabetes. The company develops Diamyd, an antigen-specific immunotherapy, which is in phase III clinical trial for the treatment of type 1 diabetes and latent autoimmune diabetes in adults (LADA); and Remygen, an immunomodulation therapy, that is in phase I/II clinical trial for the treatment of with ty… Read more